出版：MarketsandMarkets（マーケッツアンドマーケッツ） 出版年月：2023年1月
細胞および遺伝子治療製造サービス市場 : 種類（同種、自家、ウイルスベクター、非ウイルスベクター）、適応症（腫瘍学、整形外科、眼科）、用途（臨床、商業）、エンドユーザー（製薬、バイオテクノロジー） – 2027年までの世界予測
Cell & Gene Therapy Manufacturing Services Market by Type (Allogeneic, Autologous, Viral Vector, Non-viral vector), Indication (Oncology, Orthopedic, Ophthalmology), Application (Clinical, Commercial), End User (Pharma, Biotech) – Global Forecast to 2027
| ページ数 | 356 |
| 図表数 | 505 |
| 種別 | 英文調査報告書 |
| 価格 |
The global cell & gene therapy manufacturing services market size is projected to reach USD 11.5 billion by 2027 from USD 5.1 billion in 2022, at a CAGR of 17.5% during the forecast period. Growth in this market can be attributed to rapidly increasing private equity and capital investment in life sciences over the last decade coupled with significant investment in cell and gene therapy companies. This is expected to increase the demand for outsourcing, thereby increasing the growth of cell and gene therapy manufacturing services.
“Autologous segment accounted for the second largest cell therapy segment market share”
The autologous sub segment of the cell therapy segment accounted for the second largest market share. The growth of the autologous segment is attributed to the low risk of post-treatment complications compared to allogeneic stem cell therapy, the increasing number of clinical trials based on autologous types, and an increasing preference for autologous cell therapy in high-income countries.
“Infectious diseases segment accounted for the highest CAGR”
The infectious diseases segment accounted for the highest CAGR over the forecast period. Despite current drugs and treatments for infectious diseases, HIV/Aids, tuberculosis, coronavirus, Ebola virus, malaria, and respiratory tract diseases form a major concern globally. According to the Global Tuberculosis report, nearly 10 million people fall ill with tuberculosis (TB) each year. The spread of the COVID-19 pandemic has led to an increase in clinical trials for the development of cell therapies used in the treatment of coronavirus. This is expected to drive the segment growth.
“Asia Pacific: The fastest-growing country in the cell & gene therapy manufacturing services market”
The Asia Pacific offers lucrative growth potential for the cell & gene therapy manufacturing services market. This can be attributed to improved treatment techniques, the optimization of medical measures, improved medical service quality, and the dynamic adjustment of medical insurance access in countries like China. Further, high R&D expenditure by pharmaceutical companies in nations like Japan is expected to support drug development research, which will drive the growth of the cell & gene therapy manufacturing services market in the region.
The primary interviews conducted for this report can be categorized as follows:
• By Respondent: Supply Side- 70%, and Demand Side – 30%
• By Designation (Supply Side): Managers – 45%, CXOs and Directors – 30%, and Executives- 25%
• By Region: North America -40%, Europe -25%, Asia-Pacific -20%, Latin America -10%, and Middle East and Africa -5%
Lists of Companies Profiled in the Report:
• Lonza (Switzerland)
• Catalent, Inc. (US)
• Thermo Fisher Scientific, Inc. (US)
• Charles River Laboratories (US)
• WuXi AppTec (China)
• Merck KGaA (Germany)
• Takara Bio Inc. (Japan)
• Oxford Biomedica plc (UK)
• Cell and Gene Therapy Catapult (UK)
• Genezen (US)
• NIKON CORPORATION (Japan)
• FUJIFILM Holdings Corporation (Japan)
• The Discovery Labs LLC (US)
• RoslinCT (Scotland)
• JRS PHARMA (Germany)
• FinVector (Finland)
• ABL, Inc. (US)
• Resilience (US)
• BioCentriq (US)
• Porton Advanced Solutions (China)
• Andelyn Biosciences (US)
• Forge Biologics (US)
• Vibalogics (US)
• Anemocyte Srl (Italy)
• ElevateBio (US)
Research Coverage:
This report provides a detailed picture of the cell & gene therapy manufacturing services market. It aims at estimating the size and future growth potential of the market across different segments, such as type, indication, application, end user, and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall cell & gene therapy manufacturing services market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
目次
1 INTRODUCTION 54
1.1 STUDY OBJECTIVES 54
1.2 MARKET DEFINITION 54
1.2.1 INCLUSIONS AND EXCLUSIONS 55
1.3 MARKET SCOPE 56
FIGURE 1 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SEGMENTATION 56
1.3.1 YEARS CONSIDERED 57
1.4 CURRENCY 57
1.5 LIMITATIONS 57
1.6 STAKEHOLDERS 58
1.7 SUMMARY OF CHANGES 58
1.8 RECESSION IMPACT 59
2 RESEARCH METHODOLOGY 60
2.1 RESEARCH DATA 60
FIGURE 2 RESEARCH DESIGN 60
2.1.1 SECONDARY DATA 61
2.1.2 PRIMARY DATA 62
FIGURE 3 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET: BREAKDOWN OF PRIMARIES 62
2.2 MARKET SIZE ESTIMATION 63
FIGURE 4 AVERAGE MARKET SIZE ESTIMATION (2021) 63
FIGURE 5 MARKET SIZE ESTIMATION — BOTTOM-UP APPROACH (SUPPLY SIDE): COLLECTIVE REVENUE OF CELL & GENE THERAPY MANUFACTURING SERVICES IN MARKET 64
FIGURE 6 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS (2021) 65
2.3 GROWTH RATE ASSUMPTIONS 66
FIGURE 7 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET: CAGR PROJECTIONS 66
FIGURE 8 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 67
FIGURE 9 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 67
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 68
FIGURE 10 DATA TRIANGULATION METHODOLOGY 69
2.5 INSIGHTS FROM PRIMARIES 70
FIGURE 11 MARKET VALIDATION FROM PRIMARY EXPERTS 70
2.6 RESEARCH ASSUMPTIONS 70
2.7 RISK ANALYSIS 71
2.8 RECESSION IMPACT 71
TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021–2027 (% GROWTH) 71
3 EXECUTIVE SUMMARY 73
FIGURE 12 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE,
2022 VS. 2027 (USD MILLION) 73
FIGURE 13 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY INDICATION, 2022 VS. 2027 (USD MILLION) 74
FIGURE 14 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION) 74
FIGURE 15 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER, 2022 VS. 2027 (USD MILLION) 75
FIGURE 16 GEOGRAPHICAL SNAPSHOT OF CELL & GENE THERAPY MANUFACTURING SERVICES MARKET 76
4 PREMIUM INSIGHTS 77
4.1 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET OVERVIEW 77
FIGURE 17 HIGH INCIDENCE OF CANCER AND OTHER TARGET DISEASES TO DRIVE MARKET 77
4.2 NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE AND COUNTRY (2022) 78
FIGURE 18 CELL THERAPY SEGMENT ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2022 78
4.3 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SHARE, BY TYPE, 2022 VS. 2027 78
FIGURE 19 CELL THERAPY SEGMENT WILL CONTINUE TO DOMINATE MARKET IN 2027 78
4.4 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SHARE, BY END USER, 2021 79
FIGURE 20 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2021 79
4.5 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 79
FIGURE 21 ASIA PACIFIC COUNTRIES TO REGISTER HIGHEST GROWTH IN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FROM 2022 TO 2027 79
5 MARKET OVERVIEW 80
5.1 INTRODUCTION 80
5.2 MARKET DYNAMICS 80
FIGURE 22 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 80
TABLE 2 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET: IMPACT ANALYSIS 81
5.2.1 DRIVERS 81
5.2.1.1 High incidence of cancer and other target diseases 81
TABLE 3 FDA-APPROVED CAR T-CELL THERAPIES 82
5.2.1.2 Increasing pharmaceutical R&D spending 83
FIGURE 23 INCREASE IN GLOBAL PHARMACEUTICAL R&D SPENDING, 2012–2026 83
5.2.1.3 Increasing private and public investments in cell and gene therapy industry 83
5.2.1.4 Technological advancements 84
TABLE 4 TECHNOLOGIES OFFERED BY CELL & GENE THERAPY MANUFACTURING SERVICE PROVIDERS 84
5.2.1.5 Increasing partnerships and agreements between pharmaceutical companies and CDMOs 85
TABLE 5 PARTNERSHIPS BETWEEN PHARMACEUTICAL COMPANIES AND CDMOS 85
5.2.2 RESTRAINTS 86
5.2.2.1 High operational costs associated with cell & gene therapy manufacturing 86
5.2.3 OPPORTUNITIES 86
5.2.3.1 Expansion of cell and gene therapy manufacturing capacities by CDMOs 86
TABLE 6 MANUFACTURING CAPACITY EXPANSIONS BY CDMOS 87
5.2.3.2 Growing cell & gene therapies market 87
5.2.4 CHALLENGES 88
5.2.4.1 Risk of mutagenesis 88
5.2.4.2 Low yield outcomes 88
5.2.4.3 Lack of standard production systems 88
5.3 TECHNOLOGICAL ANALYSIS 88
5.4 RANGES/SCENARIOS 89
FIGURE 24 SPECTRUM OF SCENARIOS BASED ON IMPACT OF UNCERTAINTIES ON GROWTH OF CELL & GENE THERAPY MANUFACTURING SERVICES MARKET 89
5.5 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 90
FIGURE 25 REVENUE SHIFT AND NEW POCKETS FOR CELL & GENE THERAPY MANUFACTURING SERVICE PROVIDERS 90
5.6 VALUE CHAIN ANALYSIS 90
FIGURE 26 VALUE CHAIN ANALYSIS OF CELL & GENE THERAPY MANUFACTURING SERVICES MARKET: HARVESTING AND CRYOPRESERVATION PHASES ADD MAXIMUM VALUE 91
5.7 ECOSYSTEM ANALYSIS OF CELL & GENE THERAPY MANUFACTURING SERVICES MARKET 92
FIGURE 27 ECOSYSTEM ANALYSIS OF CELL & GENE THERAPY MANUFACTURING SERVICES MARKET 92
TABLE 7 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET ECOSYSTEM 92
5.8 PORTER’S FIVE FORCES ANALYSIS 94
TABLE 8 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET: PORTER’S FIVE FORCES ANALYSIS 94
5.8.1 THREAT OF NEW ENTRANTS 94
5.8.2 THREAT OF SUBSTITUTES 94
5.8.3 BARGAINING POWER OF BUYERS 94
5.8.4 BARGAINING POWER OF SUPPLIERS 95
5.8.5 INTENSITY OF COMPETITIVE RIVALRY 95
5.9 REGULATORY ANALYSIS 95
5.9.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 95
TABLE 9 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 95
TABLE 10 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 96
TABLE 11 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 97
TABLE 12 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 99
TABLE 13 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 99
5.10 KEY CONFERENCES AND EVENTS IN 2022–2023 100
TABLE 14 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET: LIST OF CONFERENCES AND EVENTS 100
5.11 KEY STAKEHOLDERS AND BUYING CRITERIA 101
FIGURE 28 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR CELL & GENE THERAPY MANUFACTURING SERVICES 101
5.12 KEY BUYING CRITERIA 102
FIGURE 29 BUYING CRITERIA OF END USERS FOR CELL & GENE THERAPY MANUFACTURING SERVICES 102
6 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE 103
6.1 INTRODUCTION 104
TABLE 15 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 104
6.2 CELL THERAPY 104
TABLE 16 CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 105
TABLE 17 CELL THERAPY MANUFACTURING SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION) 105
TABLE 18 NORTH AMERICA: CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 105
TABLE 19 EUROPE: CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 106
TABLE 20 ASIA PACIFIC: CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 106
TABLE 21 LATIN AMERICA: CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 106
6.2.1 ALLOGENEIC 107
TABLE 22 ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 107
TABLE 23 ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION) 108
TABLE 24 NORTH AMERICA: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 108
TABLE 25 EUROPE: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 108
TABLE 26 ASIA PACIFIC: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 109
TABLE 27 LATIN AMERICA: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 109
6.2.1.1 Mesenchymal stem cells 109
6.2.1.1.1 Immunosuppressive and tissue repair properties to support market growth 109
TABLE 28 ALLOGENEIC MESENCHYMAL STEM CELL MANUFACTURING SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION) 110
TABLE 29 NORTH AMERICA: ALLOGENEIC MESENCHYMAL STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 110
TABLE 30 EUROPE: ALLOGENEIC MESENCHYMAL STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 111
TABLE 31 ASIA PACIFIC: ALLOGENEIC MESENCHYMAL STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 111
TABLE 32 LATIN AMERICA: ALLOGENEIC MESENCHYMAL STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 111
6.2.1.2 T-cells 112
6.2.1.2.1 Generated by virus transduction and in vitro expansion before patient administration 112
TABLE 33 ALLOGENEIC T-CELL MANUFACTURING SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION) 112
TABLE 34 NORTH AMERICA: ALLOGENEIC T-CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 112
TABLE 35 EUROPE: ALLOGENEIC T-CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 113
TABLE 36 ASIA PACIFIC: ALLOGENEIC T-CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 113
TABLE 37 LATIN AMERICA: ALLOGENEIC T-CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 113
6.2.1.3 Induced pluripotent stem cells 114
6.2.1.3.1 Growing adoption of IPSCs in research to drive market 114
TABLE 38 ALLOGENEIC INDUCED PLURIPOTENT STEM CELL MANUFACTURING SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION) 114
TABLE 39 NORTH AMERICA: ALLOGENEIC INDUCED PLURIPOTENT STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 115
TABLE 40 EUROPE: ALLOGENEIC INDUCED PLURIPOTENT STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 115
TABLE 41 ASIA PACIFIC: ALLOGENEIC INDUCED PLURIPOTENT STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 115
TABLE 42 LATIN AMERICA: ALLOGENEIC INDUCED PLURIPOTENT STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 116
6.2.1.4 Natural killer cells 116
6.2.1.4.1 Used for advanced hepatocellular carcinoma patients 116
TABLE 43 ALLOGENEIC NATURAL KILLER CELL MANUFACTURING SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION) 116
TABLE 44 NORTH AMERICA: ALLOGENEIC NATURAL KILLER CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 117
TABLE 45 EUROPE: ALLOGENEIC NATURAL KILLER CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 117
TABLE 46 ASIA PACIFIC: ALLOGENEIC NATURAL KILLER CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 117
TABLE 47 LATIN AMERICA: ALLOGENEIC NATURAL KILLER CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 118
6.2.1.5 Hematopoietic stem cells 118
6.2.1.5.1 Stem cells from donors used for allogeneic transplantation 118
TABLE 48 ALLOGENEIC HEMATOPOIETIC STEM CELL MANUFACTURING SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION) 118
TABLE 49 NORTH AMERICA: ALLOGENEIC HEMATOPOIETIC STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 119
TABLE 50 EUROPE: ALLOGENEIC HEMATOPOIETIC STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 119
TABLE 51 ASIA PACIFIC: ALLOGENEIC HEMATOPOIETIC STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 119
TABLE 52 LATIN AMERICA: ALLOGENEIC HEMATOPOIETIC STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 120
6.2.1.6 Other allogeneic cells 120
TABLE 53 OTHER ALLOGENEIC CELL MANUFACTURING SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION) 120
TABLE 54 NORTH AMERICA: OTHER ALLOGENEIC CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 121
TABLE 55 EUROPE: OTHER ALLOGENEIC CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 121
TABLE 56 ASIA PACIFIC: OTHER ALLOGENEIC CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 121
TABLE 57 LATIN AMERICA: OTHER ALLOGENEIC CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 122
6.2.2 AUTOLOGOUS 122
TABLE 58 AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 123
TABLE 59 AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION) 123
TABLE 60 NORTH AMERICA: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 123
TABLE 61 EUROPE: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 124
TABLE 62 ASIA PACIFIC: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 124
TABLE 63 LATIN AMERICA: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 124
6.2.2.1 T-cells 125
6.2.2.1.1 Major components of adaptive immune system 125
TABLE 64 AUTOLOGOUS T-CELL MANUFACTURING SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION) 125
TABLE 65 NORTH AMERICA: AUTOLOGOUS T-CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 126
TABLE 66 EUROPE: AUTOLOGOUS T-CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 126
TABLE 67 ASIA PACIFIC: AUTOLOGOUS T-CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 126
TABLE 68 LATIN AMERICA: AUTOLOGOUS T-CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 127
6.2.2.2 Hematopoietic stem cells 127
6.2.2.2.1 Used to establish marrow and bone function 127
TABLE 69 AUTOLOGOUS HEMATOPOIETIC STEM CELL MANUFACTURING SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION) 127
TABLE 70 NORTH AMERICA: AUTOLOGOUS HEMATOPOIETIC STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 128
TABLE 71 EUROPE: AUTOLOGOUS HEMATOPOIETIC STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 128
TABLE 72 ASIA PACIFIC: AUTOLOGOUS HEMATOPOIETIC STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 128
TABLE 73 LATIN AMERICA: AUTOLOGOUS HEMATOPOIETIC STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 129
6.2.2.3 Mesenchymal stem cells 129
6.2.2.3.1 Present in umbilical cord, bone marrow, and fat tissue 129
TABLE 74 AUTOLOGOUS MESENCHYMAL STEM CELL MANUFACTURING SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION) 129
TABLE 75 NORTH AMERICA: AUTOLOGOUS MESENCHYMAL STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 130
TABLE 76 EUROPE: AUTOLOGOUS MESENCHYMAL STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 130
TABLE 77 ASIA PACIFIC: AUTOLOGOUS MESENCHYMAL STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 130
TABLE 78 LATIN AMERICA: AUTOLOGOUS MESENCHYMAL STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 131
6.2.2.4 Natural killer cells 131
6.2.2.4.1 Used in treatment of tumors and infectious diseases 131
TABLE 79 AUTOLOGOUS NATURAL KILLER CELL MANUFACTURING SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION) 131
TABLE 80 NORTH AMERICA: AUTOLOGOUS NATURAL KILLER CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 132
TABLE 81 EUROPE: AUTOLOGOUS NATURAL KILLER CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 132
TABLE 82 ASIA PACIFIC: AUTOLOGOUS NATURAL KILLER CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 132
TABLE 83 LATIN AMERICA: AUTOLOGOUS NATURAL KILLER CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 133
6.2.2.5 Other autologous cells 133
TABLE 84 OTHER AUTOLOGOUS CELL MANUFACTURING SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION) 133
TABLE 85 NORTH AMERICA: OTHER AUTOLOGOUS CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 134
TABLE 86 EUROPE: OTHER AUTOLOGOUS CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 134
TABLE 87 ASIA PACIFIC: OTHER AUTOLOGOUS CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 134
TABLE 88 LATIN AMERICA: OTHER AUTOLOGOUS CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 135
6.2.3 VIRAL VECTORS 135
TABLE 89 VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 135
TABLE 90 VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION) 136
TABLE 91 NORTH AMERICA: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 136
TABLE 92 EUROPE: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 136
TABLE 93 ASIA PACIFIC: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 137
TABLE 94 LATIN AMERICA: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 137
6.2.3.1 Retroviral vectors 137
6.2.3.1.1 Most used viral vector for cell therapy manufacturing 137
TABLE 95 RETROVIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION) 138
TABLE 96 NORTH AMERICA: RETROVIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 138
TABLE 97 EUROPE: RETROVIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 138
TABLE 98 ASIA PACIFIC: RETROVIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 139
TABLE 99 LATIN AMERICA: RETROVIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 139
6.2.3.2 Adeno-associated virus vectors 140
6.2.3.2.1 AAV vector-based techniques used for CAR T-cell therapy development 140
TABLE 100 ADENO-ASSOCIATED VIRUS VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION) 140
TABLE 101 NORTH AMERICA: ADENO-ASSOCIATED VIRUS VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 140
TABLE 102 EUROPE: ADENO-ASSOCIATED VIRUS VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 141
TABLE 103 ASIA PACIFIC: ADENO-ASSOCIATED VIRUS VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 141
TABLE 104 LATIN AMERICA: ADENO-ASSOCIATED VIRUS VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 141
6.2.3.3 Other viral vectors 142
TABLE 105 OTHER VIRUS VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION) 142
TABLE 106 NORTH AMERICA: OTHER VIRUS VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 142
TABLE 107 EUROPE: OTHER VIRUS VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 143
TABLE 108 ASIA PACIFIC: OTHER VIRUS VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 143
TABLE 109 LATIN AMERICA: OTHER VIRUS VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 143
6.3 GENE THERAPY 144
TABLE 110 GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2020–2027 (USD MILLION) 144
TABLE 111 GENE THERAPY MANUFACTURING SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION) 144
TABLE 112 NORTH AMERICA: GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 145
TABLE 113 EUROPE: GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 145
TABLE 114 ASIA PACIFIC: GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 145
TABLE 115 LATIN AMERICA: GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 146
6.3.1 VIRAL VECTORS 146
TABLE 116 VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 146
TABLE 117 VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION) 147
TABLE 118 NORTH AMERICA: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 147
TABLE 119 EUROPE: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 147
TABLE 120 ASIA PACIFIC: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 148
TABLE 121 LATIN AMERICA: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 148
6.3.1.1 Retroviral vectors 148
6.3.1.1.1 Retroviral vectors possess ability to replicate within cells 148
TABLE 122 RETROVIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION) 149
TABLE 123 NORTH AMERICA: RETROVIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 149
TABLE 124 EUROPE: RETROVIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 150
TABLE 125 ASIA PACIFIC: RETROVIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 150
TABLE 126 LATIN AMERICA: RETROVIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 150
6.3.1.2 Adeno-associated virus vectors 151
6.3.1.2.1 Small, single-stranded DNA viruses with low toxicity 151
TABLE 127 ADENO-ASSOCIATED VIRUS VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION) 151
TABLE 128 NORTH AMERICA: ADENO-ASSOCIATED VIRUS VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 152
TABLE 129 EUROPE: ADENO-ASSOCIATED VIRUS VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 152
TABLE 130 ASIA PACIFIC: ADENO-ASSOCIATED VIRUS VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 152
TABLE 131 LATIN AMERICA: ADENO-ASSOCIATED VIRUS VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 153
6.3.1.3 Other viral vectors 153
TABLE 132 OTHER VIRUS VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION) 153
TABLE 133 NORTH AMERICA: OTHER VIRUS VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 154
TABLE 134 EUROPE: OTHER VIRUS VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 154
TABLE 135 ASIA PACIFIC: OTHER VIRUS VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 154
TABLE 136 LATIN AMERICA: OTHER VIRUS VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 155
6.3.2 NON-VIRAL VECTORS 155
TABLE 137 NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 155
TABLE 138 NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION) 156
TABLE 139 NORTH AMERICA: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 156
TABLE 140 EUROPE: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 156
TABLE 141 ASIA PACIFIC: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 157
TABLE 142 LATIN AMERICA: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 157
6.3.2.1 Oligonucleotides 157
6.3.2.1.1 North America accounted for largest share of oligonucleotides market in 2021 157
TABLE 143 OLIGONUCLEOTIDE MANUFACTURING SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION) 158
TABLE 144 NORTH AMERICA: OLIGONUCLEOTIDE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 158
TABLE 145 EUROPE: OLIGONUCLEOTIDE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 158
TABLE 146 ASIA PACIFIC: OLIGONUCLEOTIDE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 159
TABLE 147 LATIN AMERICA: OLIGONUCLEOTIDE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 159
6.3.2.2 Other non-viral vectors 159
TABLE 148 OTHER NON-VIRAL VECTOR MANUFACTURING SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION) 160
TABLE 149 NORTH AMERICA: OTHER NON-VIRAL VECTOR MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 160
TABLE 150 EUROPE: OTHER NON-VIRAL VECTOR MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 160
TABLE 151 ASIA PACIFIC: OTHER NON-VIRAL VECTOR MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 161
TABLE 152 LATIN AMERICA: OTHER NON-VIRAL VECTOR MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 161
7 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET,
BY INDICATION 162
7.1 INTRODUCTION 163
TABLE 153 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY INDICATION, 2020–2027 (USD MILLION) 163
7.2 ONCOLOGY DISEASES 163
7.2.1 RISING NUMBER OF CANCER CASES WORLDWIDE TO DRIVE DEMAND FOR CELL & GENE THERAPIES 163
TABLE 154 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR ONCOLOGY DISEASES, BY REGION, 2020–2027 (USD MILLION) 164
TABLE 155 NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR ONCOLOGY DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 164
TABLE 156 EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR ONCOLOGY DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 165
TABLE 157 ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR ONCOLOGY DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 165
TABLE 158 LATIN AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR ONCOLOGY DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 165
7.3 CARDIOVASCULAR DISEASES 166
7.3.1 GROWING INCIDENCE OF CARDIOVASCULAR DISEASES OWING TO SEDENTARY LIFESTYLES TO DRIVE MARKET 166
TABLE 159 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2020–2027 (USD MILLION) 166
TABLE 160 NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 167
TABLE 161 EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 167
TABLE 162 ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 167
TABLE 163 LATIN AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 168
7.4 ORTHOPEDIC DISEASES 168
7.4.1 CELL THERAPY FOR ORTHOPEDIC DISEASES ELIMINATES POST-TREATMENT COMPLICATIONS 168
TABLE 164 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR ORTHOPEDIC DISEASES, BY REGION, 2020–2027 (USD MILLION) 168
TABLE 165 NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR ORTHOPEDIC DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 169
TABLE 166 EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR ORTHOPEDIC DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 169
TABLE 167 ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR ORTHOPEDIC DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 169
TABLE 168 LATIN AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR ORTHOPEDIC DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 170
7.5 OPHTHALMOLOGY DISEASES 170
7.5.1 STEM CELL THERAPIES USED FOR RESTORATION AND PRESERVATION OF VISION 170
TABLE 169 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR OPHTHALMOLOGY DISEASES, BY REGION, 2020–2027 (USD MILLION) 170
TABLE 170 NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR OPHTHALMOLOGY DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 171
TABLE 171 EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR OPHTHALMOLOGY DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 171
TABLE 172 ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR OPHTHALMOLOGY DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 171
TABLE 173 LATIN AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR OPHTHALMOLOGY DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 172
7.6 CENTRAL NERVOUS SYSTEM DISORDERS 172
7.6.1 INCREASING INCIDENCE OF SPINAL MUSCULAR ATROPHY TO SUPPORT MARKET GROWTH 172
TABLE 174 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR CENTRAL NERVOUS SYSTEM DISORDERS, BY REGION, 2020–2027 (USD MILLION) 172
TABLE 175 NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR CENTRAL NERVOUS SYSTEM DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION) 173
TABLE 176 EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR CENTRAL NERVOUS SYSTEM DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION) 173
TABLE 177 ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR CENTRAL NERVOUS SYSTEM DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION) 173
TABLE 178 LATIN AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR CENTRAL NERVOUS SYSTEM DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION) 174
7.7 INFECTIOUS DISEASES 174
7.7.1 INCREASING PREVALENCE OF INFECTIOUS DISEASES TO DRIVE MARKET 174
TABLE 179 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR INFECTIOUS DISEASES, BY REGION, 2020–2027 (USD MILLION) 175
TABLE 180 NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 175
TABLE 181 EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 175
TABLE 182 ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 176
TABLE 183 LATIN AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 176
7.8 OTHER INDICATIONS 176
TABLE 184 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR OTHER INDICATIONS, BY REGION, 2020–2027 (USD MILLION) 177
TABLE 185 NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 177
TABLE 186 EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 177
TABLE 187 ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 178
TABLE 188 LATIN AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 178
8 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET,
BY APPLICATION 179
8.1 INTRODUCTION 180
TABLE 189 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 180
8.2 CLINICAL MANUFACTURING 180
8.2.1 RISING NUMBER OF CLINICAL TRIALS FOR CELL & GENE THERAPIES TO DRIVE MARKET 180
TABLE 190 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR CLINICAL MANUFACTURING, BY REGION, 2020–2027 (USD MILLION) 181
TABLE 191 NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR CLINICAL MANUFACTURING, BY COUNTRY, 2020–2027 (USD MILLION) 181
TABLE 192 EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR CLINICAL MANUFACTURING, BY COUNTRY, 2020–2027 (USD MILLION) 181
TABLE 193 ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR CLINICAL MANUFACTURING, BY COUNTRY, 2020–2027 (USD MILLION) 182
TABLE 194 LATIN AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR CLINICAL MANUFACTURING, BY COUNTRY, 2020–2027 (USD MILLION) 182
8.3 COMMERCIAL MANUFACTURING 182
8.3.1 INCREASING APPROVALS OF CELL & GENE THERAPY PRODUCTS FOR COMMERCIAL MANUFACTURING TO SUPPORT MARKET GROWTH 182
TABLE 195 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR COMMERCIAL MANUFACTURING, BY REGION, 2020–2027 (USD MILLION) 183
TABLE 196 NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR COMMERCIAL MANUFACTURING, BY COUNTRY, 2020–2027 (USD MILLION) 183
TABLE 197 EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR COMMERCIAL MANUFACTURING, BY COUNTRY, 2020–2027 (USD MILLION) 183
TABLE 198 ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR COMMERCIAL MANUFACTURING, BY COUNTRY, 2020–2027 (USD MILLION) 184
TABLE 199 LATIN AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR COMMERCIAL MANUFACTURING, BY COUNTRY, 2020–2027 (USD MILLION) 184
9 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER 185
9.1 INTRODUCTION 186
TABLE 200 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION) 186
9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 186
9.2.1 GROWING NUMBER OF CELL & GENE THERAPIES IN R&D PIPELINE TO DRIVE MARKET 186
TABLE 201 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2020–2027 (USD MILLION) 187
TABLE 202 NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION) 187
TABLE 203 EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION) 188
TABLE 204 ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION) 188
TABLE 205 LATIN AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION) 189
9.3 ACADEMIC & RESEARCH INSTITUTES 189
9.3.1 INCREASE IN LIFE SCIENCES R&D EXPENDITURE TO SUPPORT MARKET GROWTH 189
TABLE 206 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2020–2027 (USD MILLION) 190
TABLE 207 NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION) 190
TABLE 208 EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION) 190
TABLE 209 ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION) 191
TABLE 210 LATIN AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION) 191
9.4 OTHER END USERS 191
TABLE 211 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR OTHER END USERS, BY REGION, 2020–2027 (USD MILLION) 192
TABLE 212 NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2020–2027 (USD MILLION) 192
TABLE 213 EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2020–2027 (USD MILLION) 192
TABLE 214 ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2020–2027 (USD MILLION) 193
TABLE 215 LATIN AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2020–2027 (USD MILLION) 193
10 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY REGION 194
10.1 INTRODUCTION 195
TABLE 216 CELL & GENE THERAPY MANUFACTURING THERAPY SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION) 195
10.2 NORTH AMERICA 195
10.2.1 RECESSION IMPACT 195
FIGURE 30 NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SNAPSHOT 196
TABLE 217 NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 197
TABLE 218 NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 197
TABLE 219 NORTH AMERICA: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 197
TABLE 220 NORTH AMERICA: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 198
TABLE 221 NORTH AMERICA: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 198
TABLE 222 NORTH AMERICA: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 199
TABLE 223 NORTH AMERICA: GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2020–2027 (USD MILLION) 199
TABLE 224 NORTH AMERICA: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 199
TABLE 225 NORTH AMERICA: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 200
TABLE 226 NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY INDICATION, 2020–2027 (USD MILLION) 200
TABLE 227 NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 200
TABLE 228 NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION) 201
10.2.2 US 201
10.2.2.1 Rising prevalence of cancer and increasing clinical trials for cell and gene therapies to drive market 201
TABLE 229 US: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 202
TABLE 230 US: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 202
TABLE 231 US: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 202
TABLE 232 US: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 203
TABLE 233 US: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 203
TABLE 234 US: GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2020–2027 (USD MILLION) 203
TABLE 235 US: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 204
TABLE 236 US: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 204
TABLE 237 US: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY INDICATION, 2020–2027 (USD MILLION) 204
TABLE 238 US: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 205
TABLE 239 US: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION) 205
10.2.3 CANADA 205
10.2.3.1 Increasing investments in stem cell research to support market 205
TABLE 240 CANADA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 206
TABLE 241 CANADA: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 206
TABLE 242 CANADA: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 207
TABLE 243 CANADA: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 207
TABLE 244 CANADA: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 208
TABLE 245 CANADA: GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2020–2027 (USD MILLION) 208
TABLE 246 CANADA: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 208
TABLE 247 CANADA: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 209
TABLE 248 CANADA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY INDICATION, 2020–2027 (USD MILLION) 209
TABLE 249 CANADA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 209
TABLE 250 CANADA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION) 210
10.3 EUROPE 210
10.3.1 RECESSION IMPACT 210
TABLE 251 EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 211
TABLE 252 EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 211
TABLE 253 EUROPE: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 211
TABLE 254 EUROPE: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 212
TABLE 255 EUROPE: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 212
TABLE 256 EUROPE: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 213
TABLE 257 EUROPE: GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2020–2027 (USD MILLION) 213
TABLE 258 EUROPE: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 213
TABLE 259 EUROPE: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 214
TABLE 260 EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY INDICATION, 2020–2027 (USD MILLION) 214
TABLE 261 EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 214
TABLE 262 EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION) 215
10.3.2 GERMANY 215
10.3.2.1 Strong growth in biotechnology industry to drive market 215
TABLE 263 GERMANY: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 215
TABLE 264 GERMANY: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 216
TABLE 265 GERMANY: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 216
TABLE 266 GERMANY: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 217
TABLE 267 GERMANY: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 217
TABLE 268 GERMANY: GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2020–2027 (USD MILLION) 217
TABLE 269 GERMANY: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 218
TABLE 270 GERMANY: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 218
TABLE 271 GERMANY: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY INDICATION, 2020–2027 (USD MILLION) 218
TABLE 272 GERMANY: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 219
TABLE 273 GERMANY: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION) 219
10.3.3 UK 219
10.3.3.1 Rising funding and growing prevalence of chronic diseases to drive market 219
TABLE 274 UK: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 220
TABLE 275 UK: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 220
TABLE 276 UK: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 221
TABLE 277 UK: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 221
TABLE 278 UK: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 222
TABLE 279 UK: GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2020–2027 (USD MILLION) 222
TABLE 280 UK: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 222
TABLE 281 UK: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 223
TABLE 282 UK: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY INDICATION, 2020–2027 (USD MILLION) 223
TABLE 283 UK: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 223
TABLE 284 UK: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION) 224
10.3.4 FRANCE 224
10.3.4.1 Availability of funds from government and private organizations to support market 224
TABLE 285 FRANCE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 224
TABLE 286 FRANCE: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 225
TABLE 287 FRANCE: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 225
TABLE 288 FRANCE: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 226
TABLE 289 FRANCE: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 226
TABLE 290 FRANCE: GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2020–2027 (USD MILLION) 226
TABLE 291 FRANCE: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 227
TABLE 292 FRANCE: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 227
TABLE 293 FRANCE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY INDICATION, 2020–2027 (USD MILLION) 227
TABLE 294 FRANCE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 228
TABLE 295 FRANCE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION) 228
10.3.5 ITALY 228
10.3.5.1 Recent developments in cell and gene therapy to drive market 228
TABLE 296 ITALY: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 229
TABLE 297 ITALY: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 229
TABLE 298 ITALY: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 230
TABLE 299 ITALY: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 230
TABLE 300 ITALY: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 231
TABLE 301 ITALY: GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2020–2027 (USD MILLION) 231
TABLE 302 ITALY: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 231
TABLE 303 ITALY: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 232
TABLE 304 ITALY: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY INDICATION, 2020–2027 (USD MILLION) 232
TABLE 305 ITALY: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 232
TABLE 306 ITALY: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION) 233
10.3.6 SPAIN 233
10.3.6.1 Rising R&D expenditure to boost market 233
TABLE 307 SPAIN: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 234
TABLE 308 SPAIN: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 234
TABLE 309 SPAIN: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 234
TABLE 310 SPAIN: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 235
TABLE 311 SPAIN: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 235
TABLE 312 SPAIN: GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2020–2027 (USD MILLION) 235
TABLE 313 SPAIN: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 236
TABLE 314 SPAIN: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 236
TABLE 315 SPAIN: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY INDICATION, 2020–2027 (USD MILLION) 236
TABLE 316 SPAIN: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 237
TABLE 317 SPAIN: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION) 237
10.3.7 REST OF EUROPE 237
TABLE 318 REST OF EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 238
TABLE 319 REST OF EUROPE: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 238
TABLE 320 REST OF EUROPE: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 238
TABLE 321 REST OF EUROPE: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 239
TABLE 322 REST OF EUROPE: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 239
TABLE 323 REST OF EUROPE: GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2020–2027 (USD MILLION) 239
TABLE 324 REST OF EUROPE: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 240
TABLE 325 REST OF EUROPE: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 240
TABLE 326 REST OF EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY INDICATION, 2020–2027 (USD MILLION) 240
TABLE 327 REST OF EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 241
TABLE 328 REST OF EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION) 241
10.4 ASIA PACIFIC 242
10.4.1 RECESSION IMPACT 242
FIGURE 31 ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SNAPSHOT 243
TABLE 329 ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 244
TABLE 330 ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 244
TABLE 331 ASIA PACIFIC: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 244
TABLE 332 ASIA PACIFIC: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 245
TABLE 333 ASIA PACIFIC: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 245
TABLE 334 ASIA PACIFIC: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 246
TABLE 335 ASIA PACIFIC: GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2020–2027 (USD MILLION) 246
TABLE 336 ASIA PACIFIC: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 246
TABLE 337 ASIA PACIFIC: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 247
TABLE 338 ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY INDICATION, 2020–2027 (USD MILLION) 247
TABLE 339 ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 247
TABLE 340 ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION) 248
10.4.2 CHINA 248
10.4.2.1 Increasing government funding and development of novel applications to drive market 248
TABLE 341 CHINA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 249
TABLE 342 CHINA: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 249
TABLE 343 CHINA: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 249
TABLE 344 CHINA: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 250
TABLE 345 CHINA: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 250
TABLE 346 CHINA: GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2020–2027 (USD MILLION) 250
TABLE 347 CHINA: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 251
TABLE 348 CHINA: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 251
TABLE 349 CHINA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY INDICATION, 2020–2027 (USD MILLION) 251
TABLE 350 CHINA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 252
TABLE 351 CHINA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION) 252
10.4.3 JAPAN 252
10.4.3.1 Robust funding coupled with growing geriatric population to propel market growth 252
TABLE 352 JAPAN: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 253
TABLE 353 JAPAN: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 253
TABLE 354 JAPAN: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 254
TABLE 355 JAPAN: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 254
TABLE 356 JAPAN: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 255
TABLE 357 JAPAN: GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2020–2027 (USD MILLION) 255
TABLE 358 JAPAN: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 255
TABLE 359 JAPAN: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 256
TABLE 360 JAPAN: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY INDICATION, 2020–2027 (USD MILLION) 256
TABLE 361 JAPAN: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 256
TABLE 362 JAPAN: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION) 257
10.4.4 INDIA 257
10.4.4.1 Growing prevalence of chronic diseases and focus on grants and collaborations for research to drive market 257
TABLE 363 INDIA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 258
TABLE 364 INDIA: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 258
TABLE 365 INDIA: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 258
TABLE 366 INDIA: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 259
TABLE 367 INDIA: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 259
TABLE 368 INDIA: GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2020–2027 (USD MILLION) 259
TABLE 369 INDIA: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 260
TABLE 370 INDIA: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 260
TABLE 371 INDIA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY INDICATION, 2020–2027 (USD MILLION) 260
TABLE 372 INDIA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 261
TABLE 373 INDIA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION) 261
10.4.5 REST OF ASIA PACIFIC 261
TABLE 374 REST OF ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 262
TABLE 375 REST OF ASIA PACIFIC: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 262
TABLE 376 REST OF ASIA PACIFIC: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 263
TABLE 377 REST OF ASIA PACIFIC: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 263
TABLE 378 REST OF ASIA PACIFIC: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 264
TABLE 379 REST OF ASIA PACIFIC: GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2020–2027 (USD MILLION) 264
TABLE 380 REST OF ASIA PACIFIC: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 264
TABLE 381 REST OF ASIA PACIFIC: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 265
TABLE 382 REST OF ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY INDICATION, 2020–2027 (USD MILLION) 265
TABLE 383 REST OF ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 265
TABLE 384 REST OF ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION) 266
10.5 LATIN AMERICA 266
10.5.1 RECESSION IMPACT 266
TABLE 385 LATIN AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 267
TABLE 386 LATIN AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 267
TABLE 387 LATIN AMERICA: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 267
TABLE 388 LATIN AMERICA: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 268
TABLE 389 LATIN AMERICA: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 268
TABLE 390 LATIN AMERICA: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 269
TABLE 391 LATIN AMERICA: GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2020–2027 (USD MILLION) 269
TABLE 392 LATIN AMERICA: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 269
TABLE 393 LATIN AMERICA: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 270
TABLE 394 LATIN AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY INDICATION, 2020–2027 (USD MILLION) 270
TABLE 395 LATIN AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 270
TABLE 396 LATIN AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION) 271
10.5.2 BRAZIL 271
10.5.2.1 Gradual increase in pharmaceutical R&D to support market 271
TABLE 397 BRAZIL: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 271
TABLE 398 BRAZIL: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 272
TABLE 399 BRAZIL: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 272
TABLE 400 BRAZIL: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 272
TABLE 401 BRAZIL: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 273
TABLE 402 BRAZIL: GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2020–2027 (USD MILLION) 273
TABLE 403 BRAZIL: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 273
TABLE 404 BRAZIL: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 274
TABLE 405 BRAZIL: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY INDICATION, 2020–2027 (USD MILLION) 274
TABLE 406 BRAZIL: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 274
TABLE 407 BRAZIL: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION) 275
10.5.3 MEXICO 275
10.5.3.1 Favorable government policies in Mexico to support market 275
TABLE 408 MEXICO: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 275
TABLE 409 MEXICO: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 276
TABLE 410 MEXICO: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 276
TABLE 411 MEXICO: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 277
TABLE 412 MEXICO: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 277
TABLE 413 MEXICO: GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2020–2027 (USD MILLION) 277
TABLE 414 MEXICO: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 278
TABLE 415 MEXICO: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 278
TABLE 416 MEXICO: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY INDICATION, 2020–2027 (USD MILLION) 278
TABLE 417 MEXICO: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 279
TABLE 418 MEXICO: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION) 279
10.5.4 REST OF LATIN AMERICA 279
TABLE 419 REST OF LATIN AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 280
TABLE 420 REST OF LATIN AMERICA: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 280
TABLE 421 REST OF LATIN AMERICA: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 280
TABLE 422 REST OF LATIN AMERICA: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 281
TABLE 423 REST OF LATIN AMERICA: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 281
TABLE 424 REST OF LATIN AMERICA: GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2020–2027 (USD MILLION) 281
TABLE 425 REST OF LATIN AMERICA: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 282
TABLE 426 REST OF LATIN AMERICA: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 282
TABLE 427 REST OF LATIN AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY INDICATION, 2020–2027 (USD MILLION) 282
TABLE 428 REST OF LATIN AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 283
TABLE 429 REST OF LATIN AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION) 283
10.6 MIDDLE EAST & AFRICA 283
10.6.1 CHANGING DEMOGRAPHICS AND FAVORABLE POLICIES FOR PHARMACEUTICAL R&D TO DRIVE MARKET 283
10.6.2 RECESSION IMPACT 284
TABLE 430 MIDDLE EAST & AFRICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 284
TABLE 431 MIDDLE EAST & AFRICA: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 285
TABLE 432 MIDDLE EAST & AFRICA: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 285
TABLE 433 MIDDLE EAST & AFRICA: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 286
TABLE 434 MIDDLE EAST & AFRICA: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 286
TABLE 435 MIDDLE EAST & AFRICA: GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2020–2027 (USD MILLION) 286
TABLE 436 MIDDLE EAST & AFRICA: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 287
TABLE 437 MIDDLE EAST & AFRICA: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 287
TABLE 438 MIDDLE EAST & AFRICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY INDICATION, 2020–2027 (USD MILLION) 287
TABLE 439 MIDDLE EAST & AFRICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 288
TABLE 440 MIDDLE EAST & AFRICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION) 288
11 COMPETITIVE LANDSCAPE 289
11.1 OVERVIEW 289
11.2 STRATEGIES ADOPTED BY KEY PLAYERS 289
FIGURE 32 KEY PLAYER STRATEGIES IN CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, 2019–2022 289
11.3 MARKET SHARE ANALYSIS 290
FIGURE 33 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SHARE ANALYSIS, BY KEY PLAYER, 2021 290
TABLE 441 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET: DEGREE OF COMPETITION 290
11.4 REVENUE SHARE ANALYSIS 291
FIGURE 34 REVENUE SHARE ANALYSIS OF KEY MARKET PLAYERS 291
11.5 COMPANY EVALUATION QUADRANT 292
11.5.1 STARS 292
11.5.2 EMERGING LEADERS 292
11.5.3 PERVASIVE PLAYERS 292
11.5.4 PARTICIPANTS 292
FIGURE 35 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET: COMPANY EVALUATION QUADRANT, 2021 293
11.6 COMPANY EVALUATION QUADRANT FOR STARTUPS/SMES 294
11.6.1 PROGRESSIVE COMPANIES 294
11.6.2 STARTING BLOCKS 294
11.6.3 RESPONSIVE COMPANIES 294
11.6.4 DYNAMIC COMPANIES 294
FIGURE 36 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET: COMPANY EVALUATION QUADRANT FOR STARTUPS/SMES, 2021 295
11.7 COMPETITIVE BENCHMARKING OF STARTUPS/SMES 296
TABLE 442 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET: DETAILED LIST OF KEY STARTUPS/SMES 296
TABLE 443 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES 297
11.8 COMPETITIVE BENCHMARKING OF TOP 25 PLAYERS 297
11.8.1 COMPANY FOOTPRINT 297
TABLE 444 COMPANY FOOTPRINT ANALYSIS OF KEY PLAYERS 297
11.8.2 SERVICE FOOTPRINT 298
TABLE 445 SERVICE FOOTPRINT ANALYSIS OF KEY PLAYERS 298
11.8.3 APPLICATION FOOTPRINT 299
TABLE 446 APPLICATION FOOTPRINT ANALYSIS OF KEY PLAYERS 299
11.8.4 REGIONAL FOOTPRINT 300
TABLE 447 REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS 300
11.9 COMPETITIVE SCENARIO AND TRENDS 301
11.9.1 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET: DEALS, JANUARY 2019–DECEMBER 2022 301
11.9.2 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET: SERVICE LAUNCHES, JANUARY 2019–DECEMBER 2022 303
11.9.3 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET: OTHER DEVELOPMENTS, JANUARY 2019–DECEMBER 2022 303
12 COMPANY PROFILES 305
12.1 KEY MARKET PLAYERS 305
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
12.1.1 LONZA 305
TABLE 448 LONZA: BUSINESS OVERVIEW 305
FIGURE 37 LONZA: COMPANY SNAPSHOT (2021) 306
12.1.2 CATALENT, INC. 312
TABLE 449 CATALENT, INC.: BUSINESS OVERVIEW 312
FIGURE 38 CATALENT, INC.: COMPANY SNAPSHOT (2021) 313
12.1.3 THERMO FISHER SCIENTIFIC, INC. 320
TABLE 450 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW 320
FIGURE 39 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2021) 321
12.1.4 MERCK KGAA 325
TABLE 451 MERCK KGAA: BUSINESS OVERVIEW 325
FIGURE 40 MERCK KGAA: COMPANY SNAPSHOT (2021) 326
12.1.5 CHARLES RIVER LABORATORIES 330
TABLE 452 CHARLES RIVER LABORATORIES: BUSINESS OVERVIEW 330
FIGURE 41 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT (2021) 331
12.1.6 TAKARA BIO INC. 335
TABLE 453 TAKARA BIO INC.: BUSINESS OVERVIEW 335
FIGURE 42 TAKARA BIO INC.: COMPANY SNAPSHOT (2021) 336
12.1.7 OXFORD BIOMEDICA PLC 339
TABLE 454 OXFORD BIOMEDICA PLC: BUSINESS OVERVIEW 339
FIGURE 43 OXFORD BIOMEDICA PLC: COMPANY SNAPSHOT (2021) 339
12.1.8 CELL AND GENE THERAPY CATAPULT 343
TABLE 455 CELL AND GENE THERAPY CATAPULT: BUSINESS OVERVIEW 343
FIGURE 44 CELL AND GENE THERAPY CATAPULT: COMPANY SNAPSHOT (2021) 343
12.1.9 FUJIFILM HOLDINGS CORPORATION 347
TABLE 456 FUJIFILM HOLDINGS CORPORATION: BUSINESS OVERVIEW 347
FIGURE 45 FUJIFILM HOLDINGS CORPORATION: COMPANY SNAPSHOT (2021) 348
12.1.10 WUXI APPTEC 352
TABLE 457 WUXI APPTEC: BUSINESS OVERVIEW 352
FIGURE 46 WUXI APPTEC: COMPANY SNAPSHOT (2021) 353
12.1.11 NIKON CORPORATION 357
TABLE 458 NIKON CORPORATION: BUSINESS OVERVIEW 357
FIGURE 47 NIKON CORPORATION: COMPANY SNAPSHOT (2021) 358
12.2 OTHER PLAYERS 359
12.2.1 THE DISCOVERY LABS 359
12.2.2 ROSLINCT 359
12.2.3 JRS PHARMA 360
12.2.4 FINVECTOR 361
12.2.5 ABL, INC. 361
12.2.6 RESILIENCE, INC. 362
12.2.7 BIOCENTRIQ 362
12.2.8 PORTON ADVANCED SOLUTIONS 363
12.2.9 ANDELYN BIOSCIENCES 363
12.2.10 GENEZEN 364
12.2.11 VIBALOGICS 364
12.2.12 ANEMOCYTE SRL 365
12.2.13 ELEVATE BIO 365
12.2.14 FORGE BIOLOGICS 366
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
13 APPENDIX 367
13.1 DISCUSSION GUIDE 367
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 373
13.3 CUSTOMIZATION OPTIONS 375
13.4 RELATED REPORTS 375
13.5 AUTHOR DETAILS 376